Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of CAM2029 versus octreotide LAR or lanreotide autogel in unresectable/metastatic well-differentiated GEP-NET
NL-OMON60568Phase 3Active, not recruiting
- Sponsor
- Camurus
- Start
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide hydrochloride, octreotide and lanreotide in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Camurus. Primary endpoint: Progression-free survival. Started May 2022; status: active, not recruiting.
02
Drugs
octreotide hydrochlorideoctreotidelanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON60568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60568.